| Title |
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, September 2019
|
| DOI | 10.1186/s40425-019-0706-x |
| Pubmed ID | |
| Authors |
Marijo Bilusic, Christopher R. Heery, Julie M. Collins, Renee N. Donahue, Claudia Palena, Ravi A. Madan, Fatima Karzai, Jennifer L. Marté, Julius Strauss, Margaret E. Gatti-Mays, Jeffrey Schlom, James L. Gulley |
X Demographics
The data shown below were collected from the profiles of 27 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 16 | 59% |
| Brazil | 1 | 4% |
| Japan | 1 | 4% |
| Italy | 1 | 4% |
| Unknown | 8 | 30% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 48% |
| Practitioners (doctors, other healthcare professionals) | 5 | 19% |
| Scientists | 5 | 19% |
| Science communicators (journalists, bloggers, editors) | 4 | 15% |
Mendeley readers
The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 105 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 13% |
| Researcher | 13 | 12% |
| Student > Master | 10 | 10% |
| Student > Bachelor | 10 | 10% |
| Student > Doctoral Student | 8 | 8% |
| Other | 17 | 16% |
| Unknown | 33 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 20% |
| Biochemistry, Genetics and Molecular Biology | 11 | 10% |
| Immunology and Microbiology | 8 | 8% |
| Agricultural and Biological Sciences | 4 | 4% |
| Computer Science | 3 | 3% |
| Other | 16 | 15% |
| Unknown | 42 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 35. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 February 2024.
All research outputs
#1,159,066
of 25,604,262 outputs
Outputs from Journal for Immunotherapy of Cancer
#275
of 3,470 outputs
Outputs of similar age
#24,145
of 351,301 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#5
of 75 outputs
Altmetric has tracked 25,604,262 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,470 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 351,301 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 75 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.